The dementia care market is expanding on two fronts in 2025: steady growth in patient demand and a new class of costly, tightly regulated drugs. Roughly 7.2 million Americans age 65 and older have Alzheimer's dementia this year, a number the Alzheimer's Association projects will reach about 13 million by 2050 — the core force pulling the market upward. Dementia is a broad term for loss of memory and thinking severe enough to disrupt daily life; Alzheimer's disease is its most common cause. This update covers what is actually changing right now — costs, drug prices, coverage rules, and where analysts expect growth — so you can separate verified facts from marketing estimates.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is driving demand and cost right now?
- What do the new drugs cost, and who pays?
- What changed in the treatment lineup?
- The limits every reader should weigh
- Regional and market-size estimates — read with caution
- Frequently Asked Questions
What is driving demand and cost right now?
Demand is demographic. As the 65-and-older population grows, the number of people living with Alzheimer's dementia climbs, and that expansion sets the pace for care services, drugs, and support products. The dollars involved are large. The Alzheimer's Association projects 2025 U.S.
dementia care costs at $384 billion, not counting unpaid care. On top of that, families provide an estimated 19.2 billion hours of unpaid care, valued at $413 billion — a hidden cost that shapes household budgets more than any market figure. For a reader planning care, the takeaway is simple: the paid market is only half the picture. Unpaid family labor carries a cost roughly equal to the entire formal care bill.
What do the new drugs cost, and who pays?
The most visible price story is anti-amyloid drugs — medicines that clear amyloid protein plaques from the brain. leqembi (lecanemab) carries a list price of about $26,500 per year, with traditional-Medicare patients facing more than $5,000 annually out of pocket at 20% coinsurance, according to KFF. Coverage exists but comes with conditions.
Since full FDA approval in July 2023, CMS covers anti-amyloid drugs only for confirmed mild cognitive impairment or mild dementia with amyloid pathology, and only through a qualifying patient registry. That registry requirement is a real gatekeeper, not a formality. The fiscal weight is significant. CMS projected Medicare spending on Leqembi alone could reach about $3.5 billion in the year after broad coverage — one drug carrying billions in new spending.
What changed in the treatment lineup?
Two approvals reshaped the market. The fda approved Kisunla (donanemab) on July 2, 2024, for early symptomatic Alzheimer's with confirmed amyloid, and a July 2025 label update added modified titration to reduce the risk of ARIA — brain swelling or bleeding seen with these drugs.
Delivery is also getting easier. On August 29, 2025, the FDA approved Leqembi IQLIK, a subcutaneous weekly autoinjector for maintenance dosing after 18 months of IV therapy in early Alzheimer's. That shifts some care from the infusion clinic toward the home, which matters for both access and cost.
The limits every reader should weigh
These drugs are not a cure. They are amyloid-clearing treatments that slow early-stage decline; they do not reverse or stop the disease.
They also carry real safety demands. Because of the ARIA risk, patients need baseline and serial MRI scans, and eligibility is narrow — confirmed early-stage disease with amyloid pathology. Before assuming a drug is an option, check the basics: If any of these do not fit, the newest drugs likely are not the right path — and that narrow eligibility is a key reason the treatment market stays smaller than the demand numbers suggest.
- Diagnosis is mild cognitive impairment or mild dementia, not moderate or advanced disease
- Amyloid presence is confirmed by testing
- You can commit to repeat MRI monitoring for brain swelling or bleeding
- Your care is delivered through a CMS-qualifying registry for coverage
Regional and market-size estimates — read with caution
Analyst forecasts point to growth, but treat them as estimates, not verified facts. Third-party firms peg the 2026 dementia-care/products market somewhere between roughly $18.6 billion and $26.7 billion, at about 7–8% annual growth, with home-based care the fastest-growing segment.
That wide range — a gap of several billion dollars — signals how uncertain these projections are. The one consistent theme worth watching is the shift toward home-based care, which aligns with the new at-home drug delivery and with families shouldering most unpaid care. If you want to track where treatment is actually heading, the recruiting-trials registry at ClinicalTrials.gov lists active Alzheimer's studies you can search by condition and status.
Frequently Asked Questions
Does Medicare pay for the new Alzheimer's drugs?
Yes, but only for confirmed mild cognitive impairment or mild dementia with amyloid pathology, and only through a qualifying patient registry.
Can I take Leqembi at home now?
The FDA approved a weekly at-home autoinjector version, Leqembi IQLIK, on August 29, 2025, for maintenance dosing after 18 months of IV therapy.
Do these drugs cure or reverse dementia?
No. They clear amyloid and slow early-stage decline; they do not reverse or stop the disease, and they require MRI monitoring for brain swelling or bleeding.
